Baird analyst Eric Coldwell has reiterated an 'Outperform' rating on Cardinal Health (CAH) and increased its price target from $251 to $274. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their valuation models.
Baird analyst Eric Coldwell maintained an 'Outperform' rating on Cardinal Health (CAH) and raised the price target from $251 to $274. This action signals increased confidence from the analyst in CAH's future performance and valuation. For traders, this could lead to short-term positive sentiment and potentially increased buying activity as investors react to the higher price target. The long-term implication is a reinforced positive outlook for the company, though actual stock movement will depend on broader market conditions and company fundamentals. The key opportunity for traders is to capitalize on any immediate upward momentum following this analyst upgrade.